J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion
- Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, or $132 per share, marking the largest biotechnology acquisition since early 2023.
- The acquisition focuses on Intra-Cellular's drug Caplyta, which treats schizophrenia and bipolar depression, and may expand to major depressive disorder.
- J&J's CEO Joaquin Duato stated the deal builds on the company's nearly 70-year legacy in neuroscience and commitment to advancing care.
- Analysts see the acquisition as a strategic move for J&J to strengthen its neuroscience portfolio amid challenges from patent expirations.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left5Leaning Right2Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 36%
C 50%
14%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
